March 6 (Reuters) - A U.S. federal judge has denied an

injunction that would have allowed compounding pharmacies to

keep making copies of Eli Lilly's ( LLY ) popular weight-loss

drug Zepbound in the U.S.

The decision was filed late on Wednesday in response to a

lawsuit brought by a compounding industry group that challenged

the U.S. Food and Drug Administration's decision to bar those

copies.